Side-by-side comparison of AI visibility scores, market position, and capabilities
SF no-code computational biology API democratizing AlphaFold and protein engineering tools for pharma and biotech; YC W24 $14.1M with $13.6M Series A May 2025 serving thousands of researchers without bioinformatics infrastructure.
Tamarind Bio is a San Francisco-based computational biology platform — backed by Y Combinator (W24) with $14.1 million raised including a $500,000 seed in 2024 and a $13.6 million Series A in May 2025 — providing pharmaceutical companies, biotechs, and academic researchers with no-code API access to advanced computational biology tools (AlphaFold protein structure prediction, antibody engineering models, protein-protein interaction prediction, molecular dynamics simulation) that historically required high-performance computing infrastructure, specialized bioinformatics expertise, and weeks of computational time to run. Founded in 2023 with a 7-person team, Tamarind serves thousands of researchers across large pharma companies, biotech startups, and academic institutions that need computational biology capabilities without building or maintaining HPC infrastructure.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.